$CYRX

SHELTON JERRELL sold $429K of CYRX

SHELTON JERRELL (President, CEO) sold 28,800 shares of Cryoport, Inc. (CYRX) at $14.91 ($0.43M total) on 2026-08-11 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · SHELTON JERRELL
Published Aug 11, 2026, 10:49 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 11, 2026, 10:53 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CYRX
Neutral
high confidence
Mentioned
$CYRX
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CYRXNeutralLow
01

Why it matters

The disclosure updates the record of insider selling activity but does not provide new company performance, guidance, or regulatory developments.

02

Market read

Traders may monitor insider activity, but this specific filing is unlikely to change valuation without accompanying fundamental news.

03

What to watch

10b5-1 plans are pre-scheduled and often used for liquidity diversification, so the sale may not reflect new information about Cryoport’s prospects.

Relevance 3/10Novelty 2/10Timing: filed on 2026-08-11 (after-hours)

Background

The article is a SEC Form 4 insider transaction disclosure for Cryoport, Inc.

Company-level read

Ticker impact

$CYRXNeutralHigh confidence
Context

Cryoport CEO Shelton Jerrell filed a Form 4 selling 28,800 shares at $14.9092 on 2026-08-11 under a 10b5-1 plan.

Expected impact

Likely limited near-term impact; any effect would be sentiment-driven rather than fundamentals.

Evidence & confidence

Form 4 insider sales, even by top executives, typically have muted price impact unless tied to new guidance, investigations, or unusual circumstances; the filing specifies a pre-arranged 10b5-1 plan.

Market effects

No clear sector read-through from a routine 10b5-1 insider sale.

None indicated.

None indicated.

Counterpoint

A large CEO sale can still be interpreted by some traders as reduced confidence, even if executed under a 10b5-1 plan.

Key entities

  • Cryoport, Inc.

    Subject of the Form 4 insider sale by its CEO.

  • Shelton Jerrell

    President and CEO who sold shares via an open-market transaction under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CYRXMedAI 8/10

Cryoport (CYRX) Q2 2026 Earnings Call Transcript

Cryoport (CYRX) reported Q2 2026 revenue of $49 million, up from prior periods, led by Life Science Services. Life Science Services revenue rose 15% year over year, with biostorage and bioservices up 25%. Support for commercial cell and gene therapy rose 9% to $9.4 million. Adjusted EBITDA turned positive at $0.4 million. Full-year 2026 revenue guidance remains $192 million to $196 million.

$CYRXMed

Cryoport, Inc. (CYRX): Results of Operations and Financial Condition

Cryoport, Inc. (CYRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Cryoport Reports Second Quarter 2026 Financial Results · Second quarter revenue grew 8% year-over-year to $49.0 million · Life Sciences Services revenue increased 15% year-over-year · BioStorage/BioServices revenue grew 25% year-over-year · Supporting 779 global clin